Self-activation of Vγ9Vδ2 T cells by exogenous phosphoantigens involves TCR and butyrophilins.
Butyrophilins
Phosphoantigen
T-cell receptor
Vγ9Vδ2 T cells
Journal
Cellular & molecular immunology
ISSN: 2042-0226
Titre abrégé: Cell Mol Immunol
Pays: China
ID NLM: 101242872
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
30
03
2021
accepted:
04
06
2021
pubmed:
30
6
2021
medline:
1
4
2022
entrez:
29
6
2021
Statut:
ppublish
Résumé
The high cytotoxic activity of Vγ9Vδ2 T lymphocytes against tumor cells makes them useful candidates in anticancer therapies. However, the molecular mechanism of their activation by phosphoantigens (PAgs) is not completely known. Many studies have depicted the mechanism of Vγ9Vδ2 T-cell activation by PAg-sensed accessory cells, such as immune presenting cells or tumor cells. In this study, we demonstrated that pure resting Vγ9Vδ2 T lymphocytes can self-activate through exogenous PAgs, involving their TCR and the butyrophilins BTN3A1 and BTN2A1. This is the first time that these three molecules, concurrently expressed at the plasma membrane of Vγ9Vδ2 T cells, have been shown to be involved together on the same and unique T cell during PAg activation. Moreover, the use of probucol to stimulate the inhibition of this self-activation prompted us to propose that ABCA-1 could be implicated in the transfer of exogenous PAgs inside Vγ9Vδ2 T cells before activating them through membrane clusters formed by γ9TCR, BTN3A1 and BTN2A1. The self-activation of Vγ9Vδ2 T cells, which leads to self-killing, can therefore participate in the failure of γδ T cell-based therapies with exogenous PAgs and should be taken into account.
Identifiants
pubmed: 34183807
doi: 10.1038/s41423-021-00720-w
pii: 10.1038/s41423-021-00720-w
pmc: PMC8237548
doi:
Substances chimiques
Antigens, CD
0
Butyrophilins
0
Receptors, Antigen, T-Cell, gamma-delta
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1861-1870Informations de copyright
© 2021. The Author(s), under exclusive licence to CSI and USTC.
Références
Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol. 1995;154:3932–40.
pubmed: 7706731
Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol. 2004;173:6767–76.
pubmed: 15557170
doi: 10.4049/jimmunol.173.11.6767
pmcid: 15557170
Sicard H, Ingoure S, Luciani B, Serraz C, Fournié J-J, Bonneville M, et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol. 2005;175:5471–80.
pubmed: 16210655
doi: 10.4049/jimmunol.175.8.5471
Rei M, Pennington DJ, Silva-Santos B. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy. Cancer Res. 2015;75:798–802.
pubmed: 25660949
doi: 10.1158/0008-5472.CAN-14-3228
Donia M, Ellebaek E, Andersen MH, Straten PT, Svane IM. Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes. OncoImmunology. 2012;1:1297–304.
pubmed: 23243593
pmcid: 3518502
doi: 10.4161/onci.21659
Wang J, Lin C, Li H, Li R, Wu Y, Liu H, et al. Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. OncoImmunology. 2017;6:e1353858.
pubmed: 29147601
pmcid: 5674957
doi: 10.1080/2162402X.2017.1353858
Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived T cells of MICA and MICB. Proc Natl Acad Sci. 1999;96:6879–84.
pubmed: 10359807
pmcid: 22010
doi: 10.1073/pnas.96.12.6879
Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier J-F, Scotet E, et al. Vγ9Vδ2 T cell response to colon carcinoma cells. J Immunol. 2005;175:5481–8.
pubmed: 16210656
doi: 10.4049/jimmunol.175.8.5481
Sebestyen Z, Prinz I, Déchanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. 2020;19:169–84.
pubmed: 31492944
doi: 10.1038/s41573-019-0038-z
Poupot M, Fournié J-J. Non-peptide antigens activating human Vγ9/Vδ2 T lymphocytes. Immunol Lett. 2004;95:129–38.
pubmed: 15388252
doi: 10.1016/j.imlet.2004.06.013
pmcid: 15388252
Gober H-J, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163–8.
pubmed: 12538656
pmcid: 2193814
doi: 10.1084/jem.20021500
Hebbeler AM, Cairo C, Cummings JS, Pauza CD. Individual Vγ2-Jγ1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens. Cancer Immunol Immunother. 2007;56:819–29.
pubmed: 17131122
pmcid: 2948954
doi: 10.1007/s00262-006-0235-6
Hoeres T, Holzmann E, Smetak M, Birkmann J, Wilhelm M. PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-cells in response to leukemia. Oncoimmunology. 2019;8:1550618.
pubmed: 30723581
doi: 10.1080/2162402X.2018.1550618
pmcid: 30723581
Rossi C, Gravelle P, Decaup E, Bordenave J, Poupot M, Tosolini M, et al. Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. Oncoimmunology. 2019;8:1554175.
pubmed: 30723586
doi: 10.1080/2162402X.2018.1554175
pmcid: 30723586
Ono K, Onishi Y, Kobayashi M, Hatta S, Nasu K, Watanabe S, et al. γδ T cell clonal proliferation early after PD-1 blockade. Ann Hematol. 2019;98:219–20.
pubmed: 29946908
doi: 10.1007/s00277-018-3406-6
Chauvin C, Joalland N, Perroteau J, Jarry U, Lafrance L, Willem C, et al. NKG2D controls natural reactivity of Vγ9Vδ2 T lymphocytes against mesenchymal glioblastoma cells. Clin Cancer Res. 2019;25:7218–28.
pubmed: 31506386
doi: 10.1158/1078-0432.CCR-19-0375
pmcid: 31506386
Chitadze G, Lettau M, Luecke S, Wang T, Janssen O, Fürst D, et al. NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors. Oncoimmunology. 2016;5:e1093276.
pubmed: 27141377
doi: 10.1080/2162402X.2015.1093276
Harly C, Guillaume Y, Nedellec S, Peigné C-M, Mönkkönen H, Mönkkönen J, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood. 2012;120:2269–79.
pubmed: 22767497
pmcid: 3679641
doi: 10.1182/blood-2012-05-430470
Vantourout P, Laing A, Woodward MJ, Zlatareva I, Apolonia L, Jones AW, et al. Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing γδ T cell biology. Proc Natl Acad Sci USA. 2018;115:1039–44.
pubmed: 29339503
pmcid: 5798315
doi: 10.1073/pnas.1701237115
Karunakaran MM, Willcox CR, Salim M, Paletta D, Fichtner AS, Noll A, et al. Butyrophilin-2A1 directly binds germline-encoded regions of the Vγ9Vδ2 TCR and is essential for phosphoantigen sensing. Immunity. 2020;52:487–98.e6.
pubmed: 32155411
pmcid: 7083227
doi: 10.1016/j.immuni.2020.02.014
Rigau M, Ostrouska S, Fulford TS, Johnson DN, Woods K, Ruan Z, et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. Science. 2020;367. https://doi.org/10.1126/science.aay5516 .
Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, et al. RhoB mediates phosphoantigen recognition by Vγ9Vδ2 T cell receptor. Cell Rep. 2016;15:1973–85.
pubmed: 27210746
pmcid: 5035041
doi: 10.1016/j.celrep.2016.04.081
Rhodes DA, Chen H-C, Price AJ, Keeble AH, Davey MS, James LC, et al. Activation of human γδ T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin. J Immunol. 2015;194:2390–8.
pubmed: 25637025
pmcid: 4337483
doi: 10.4049/jimmunol.1401064
Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Mitro N, et al. The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells. Nat Commun. 2017;8:15663.
pubmed: 28580927
pmcid: 5465356
doi: 10.1038/ncomms15663
Belmant C, Espinosa E, Halary F, Tang Y, Peyrat M-A, Sicard H, et al. A chemical basis for selective recognition of nonpeptide antigens by human δ T cells. FASEB J. 2000;14:1669–70.
pubmed: 10973912
doi: 10.1096/fj.99-0909fje
pmcid: 10973912
Scotet E, Martinez LO, Grant E, Barbaras R, Jenö P, Guiraud M, et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity. 2005;22:71–80.
pubmed: 15664160
doi: 10.1016/j.immuni.2004.11.012
pmcid: 15664160
Manders EM, Stap J, Brakenhoff GJ, van Driel R, Aten JA. Dynamics of three-dimensional replication patterns during the S-phase, analysed by double labelling of DNA and confocal microscopy. J Cell Sci. 1992;103:857–62.
pubmed: 1478975
doi: 10.1242/jcs.103.3.857
pmcid: 1478975
Gan YH, Lui SS, Malkovsky M. Differential susceptibility of naïve and activated human gammadelta T cells to activation-induced cell death by T-cell receptor cross-linking. Mol Med Camb Mass. 2001;7:636–43.
pubmed: 11778653
pmcid: 1950068
Fisch P, Malkovsky M, Kovats S, Sturm E, Braakman E, Klein BS, et al. Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt’s lymphoma cells. Science. 1990;250:1269–73.
pubmed: 1978758
doi: 10.1126/science.1978758
pmcid: 1978758
Gertner J, Wiedemann A, Poupot M, Fournié J-J. Human gammadelta T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett. 2007;110:42–53.
pubmed: 17451812
doi: 10.1016/j.imlet.2007.03.002
Herrmann T, Fichtner AS, Karunakaran MM. An Update on the molecular basis of phosphoantigen recognition by Vγ9Vδ2 T cells. Cells. 2020;9. https://doi.org/10.3390/cells9061433 .
Yang Y, Li L, Yuan L, Zhou X, Duan J, Xiao H, et al. A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen-mediated Vγ9Vδ2 T cell activation. Immunity. 2019;50:1043–53.e5.
pubmed: 30902636
doi: 10.1016/j.immuni.2019.02.016
pmcid: 30902636
Dustin ML, Scotet E, Olive D. An X-ray vision for phosphoantigen recognition. Immunity. 2019;50:1026–8.
pubmed: 30995494
doi: 10.1016/j.immuni.2019.03.015
Lang F, Peyrat MA, Constant P, Davodeau F, David-Ameline J, Poquet Y, et al. Early activation of human V gamma 9V delta 2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands. J Immunol. 1995;154:5986–94.
pubmed: 7751641
pmcid: 7751641
Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, Romagné F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem. 2001;276:18337–44.
pubmed: 11279081
doi: 10.1074/jbc.M100495200
Martinet L, Fleury-Cappellesso S, Gadelorge M, Dietrich G, Bourin P, Fournié J-J, et al. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells. Eur J Immunol. 2009;39:752–62.
pubmed: 19197941
doi: 10.1002/eji.200838812
pmcid: 19197941
Martinet L, Poupot R, Mirshahi P, Rafii A, Fournié J-J, Mirshahi M, et al. Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer. 2010;126:2143–52.
pubmed: 19739080
Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature. 1995;375:155–8.
pubmed: 7753173
doi: 10.1038/375155a0
pmcid: 7753173
Joseph N, Reicher B, Barda-Saad M. The calcium feedback loop and T cell activation: how cytoskeleton networks control intracellular calcium flux. Biochim Biophys Acta. 2014;1838:557–68.
pubmed: 23860253
doi: 10.1016/j.bbamem.2013.07.009
Serrano R, Wesch D, Kabelitz D. Correction: Serrano, R.; Wesch, D.; Kabelitz, D. Activation of human γδ T cells: modulation by toll-like receptor 8 ligands and role of monocytes. Cells 2020, 9, 713. Cells. 2020;9. https://doi.org/10.3390/cells9091977 .
Riganti C, Castella B, Massaia M. ABCA1, apoA-I, and BTN3A1: a legitimate ménage à Trois in dendritic cells. Front Immunol. 2018;9:1246.
pubmed: 29937767
pmcid: 6002486
doi: 10.3389/fimmu.2018.01246
Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, et al. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother. 2010;59:1611–9.
pubmed: 20582413
doi: 10.1007/s00262-010-0887-0
D'asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol. 2010;184:3260–8.
pubmed: 20154204
doi: 10.4049/jimmunol.0903454
Sandstrom A, Peigné C-M, Léger A, Crooks JE, Konczak F, Gesnel M-C, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity. 2014;40:490–500.
pubmed: 24703779
pmcid: 4028361
doi: 10.1016/j.immuni.2014.03.003
Nguyen K, Li J, Puthenveetil R, Lin X, Poe MM, Hsiao CC, et al. The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region. FASEB J. 2017;31:4697–706.
pubmed: 28705810
pmcid: 5636706
doi: 10.1096/fj.201601370RR
Sireci G, Espinosa E, Di Sano C, Dieli F, Fournié JJ, Salerno A. Differential activation of human gammadelta cells by nonpeptide phosphoantigens. Eur J Immunol. 2001;31:1628–35.
pubmed: 11465120
doi: 10.1002/1521-4141(200105)31:5<1628::AID-IMMU1628>3.0.CO;2-T
Alcover A, Alarcón B. Internalization and intracellular fate of TCR-CD3 complexes. Crit Rev Immunol. 2000;20:325–46.
pubmed: 11100805
doi: 10.1615/CritRevImmunol.v20.i4.20
Nedellec S, Sabourin C, Bonneville M, Scotet E. NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol. 2010;185:55–63.
pubmed: 20511557
doi: 10.4049/jimmunol.1000373
Efferth T. Adenosine triphosphate-binding cassette transporter genes in ageing and age-related diseases. Ageing Res Rev. 2003;2:11–24.
pubmed: 12437993
doi: 10.1016/S1568-1637(02)00046-6
Perez J, Dansou B, Hervé R, Levi C, Tamouza H, Vandermeersch S, et al. Calpains released by T lymphocytes cleave TLR2 to control IL-17 expression. J Immunol. 2016;196:168–81.
pubmed: 26608921
doi: 10.4049/jimmunol.1500749
pmcid: 26608921
Hafiane A, Genest JHDL. Atherosclerosis, and emerging therapies. Cholesterol. 2013;2013:891403.
pubmed: 23781332
pmcid: 3678415
doi: 10.1155/2013/891403
Scotet E, Martinez LO, Grant E, Barbaras R, Jenö P, Guiraud M, et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity. 2005;22:71–80.
pubmed: 15664160
doi: 10.1016/j.immuni.2004.11.012
pmcid: 15664160
Vantourout P, Mookerjee-Basu J, Rolland C, Pont F, Martin H, Davrinche C, et al. Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol. 2009;183:3848–57.
pubmed: 19710470
doi: 10.4049/jimmunol.0901085
pmcid: 19710470
Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol. 2004;24:2345–50.
pubmed: 15514211
doi: 10.1161/01.ATV.0000148706.15947.8a
pmcid: 15514211
Delvecchio CJ, Bilan P, Nair P, Capone JP. LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1. Am J Physiol Lung Cell Mol Physiol. 2008;295:L949–57.
pubmed: 18820007
doi: 10.1152/ajplung.90394.2008
pmcid: 18820007
Cubeddu LX. Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias. Curr Cardiol Rev. 2016;12:141–54.
pubmed: 26926294
pmcid: 4861943
doi: 10.2174/1573403X12666160301120217
Shi Y-Q, Fan P, Zhang G-C, Zhang Y-H, Li M-Z, Wang F, et al. Probucol-induced hERG channel reduction can be rescued by matrine and oxymatrine in vitro. Curr Pharm Des. 2020;25:4606–12.
pubmed: 31657676
doi: 10.2174/1381612825666191026170033
Laplagne C, Meddour S, Figarol S, Michelas M, Calvayrac O, Favre G, et al. Vγ9Vδ2 T cells activation through phosphoantigens can be impaired by a RHOB rerouting in lung cancer. Front Immunol. 2020;11:1396.
pubmed: 32733462
pmcid: 7358576
doi: 10.3389/fimmu.2020.01396